Recommendation of Final Dividend for the Financial Year 2025-26
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals Board has recommended a final dividend of Rs. 3.60 per equity share (36% on face value of Rs. 10) for FY2025-26, subject to shareholder approval at the ensuing AGM. The company reported strong FY2026 results with consolidated revenue of Rs. 92,035.40 million (up 16.6% YoY) and consolidated profit after tax of Rs. 9,412.69 million (up 33% YoY). Standalone PAT more than doubled to Rs. 7,329.59 million from Rs. 3,171.28 million. EPS improved to Rs. 48.77 consolidated and Rs. 38.67 standalone. Auditors issued an unmodified opinion on the audited financials. The Board also approved re-appointment of MD Satish Mehta and Whole-time Director Dr. Mukund Gurjar.
The recommendation of dividend reflects management confidence in the company's financial health following strong profit growth. Shareholders can expect steady dividend income pending approval at AGM. The robust financial performance with 33% PAT growth on consolidated basis signals solid operational execution.